Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Author:

LaCasce Ann S.1,Bociek R. Gregory2,Sawas Ahmed3,Caimi Paolo4,Agura Edward5,Matous Jeffrey6,Ansell Stephen M.7,Crosswell Howland E.8,Islas-Ohlmayer Miguel9,Behler Caroline10,Cheung Eric11,Forero-Torres Andres12,Vose Julie2,O’Connor Owen A.3,Josephson Neil13,Wang Yinghui13,Advani Ranjana14

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA;

2. Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE;

3. Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY;

4. Seidman Cancer Center, University Hospitals, Cleveland, OH;

5. Charles A. Sammons Cancer Center, Dallas, TX;

6. Colorado Blood Cancer Institute, Denver, CO;

7. Mayo Clinic, Rochester, MN;

8. St. Francis Hospital, Greenville, SC;

9. The Jewish Hospital–Mercy Health, Cincinnati, OH;

10. Pacific Hematology Oncology Associates, San Francisco, CA;

11. The Oncology Institute of Hope & Innovation, Whittier, CA;

12. Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL;

13. Seattle Genetics, Inc, Bothell, WA; and

14. Stanford Cancer Institute, Stanford, CA

Abstract

Key Points The outpatient BV and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The CR rate of 73.6% exceeded those reported for standard chemotherapy regimens, and post-ASCT outcomes generally appeared excellent.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 193 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3